Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review identified alopecia as a significant cosmetic side effect of antiseizure medications, particularly with valproate, lamotrigine, and carbamazepine, noting that hair loss often improves after dose adjustment.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

The document concludes that more research is needed to confirm if COVID-19 vaccines cause a type of hair loss called alopecia areata.

This review discusses anticoagulant and antihypertensive medications as potential contributors to medication-induced telogen effluvium and reports no new clinical results.

This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.

COVID-19 vaccines have been linked to an increase in hair loss conditions.

Oral retinoids like isotretinoin and acitretin can cause significant hair loss.

This review highlights the role of sex hormones in skin health, observing that hormonal changes throughout a woman's life can affect skin conditions such as acne and hair loss, with treatments involving hormonal therapies and the importance of a multidisciplinary approach.

This study found that fluconazole induced early hair follicle resting phase (telogen effluvium) in rats, without changing retinoic acid levels in rats or human patients, suggesting further investigation into fluconazole's hair loss mechanism is needed.

Chronic kidney disease can cause hair loss, which may be related to zinc deficiency or certain medications, and sometimes hair grows back when the underlying issue is treated.

This report describes the first known case of alopecia in a 16-year-old patient associated with quetiapine use, which resolved after stopping the medication.

This review discusses the wide range of drugs potentially causing reversible or irreversible hair loss and emphasizes the difficulty of diagnosing drug-induced alopecia without withdrawal of the suspected medication; it reports no new clinical findings.

Phenytoin, a medication, can cause hair loss and trigger a condition similar to lupus.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

This study found that sensor-controlled scalp cooling was effective in preventing hair loss during chemotherapy, particularly in premenopausal patients and those without systemic comorbidities or additional medications.

This study found that drug-induced alopecia areata was most commonly associated with TNF-alpha inhibitors and dupilumab, with most cases improving after discontinuing the medication.

In this case study involving a two-month-old crossbred kid, severe skin conditions characterized by alopecia and pruritic lesions were linked to Malassezia yeast and bacteria, and successful treatment was observed with ketoconazole and supportive care.

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

In this case study, a Pomeranian was diagnosed with vaccine-induced ischemic dermatopathy, where different medication regimens gradually improved hair regrowth, though some lesions persisted after tapering treatment.

In a retrospective study, TNFα inhibitor-induced alopecia was observed in pediatric patients, primarily adolescents with inflammatory bowel diseases, with hair regrowth occurring in those who discontinued the therapy; this suggests that stopping these medications can improve drug-induced alopecia in children.

In this study, 45 patients with advanced basal cell carcinoma treated with the medication sonidegib experienced a 24% incidence of alopecia, with detailed trichoscopic and LC-OCT examination revealing specific hair changes, suggesting LC-OCT might help identify early signs of alopecia from sonidegib use.

This review discusses the potential for mood stabilizers, antidepressants, and some antipsychotic and antianxiety drugs to induce alopecia and reports no clinical results.

This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.

Hair loss in women often doesn't follow a pattern, isn't linked to age, may be genetic, and can be related to thyroid issues or other health factors.

This review discusses the concept of telogen effluvium and emphasizes that its diagnosis requires detailed clinical evaluation and tests to identify underlying causes; no new clinical results are reported.

This study found that scalp cooling resulted in visible hair retention in 53% of breast cancer patients undergoing Epirubicin/Cyclophosphamide and Paclitaxel treatment, with factors like hair bulb diameter, shaft diameter, and anagen rate significantly predicting outcomes.

This study found that sensor-controlled scalp cooling prevented visible hair loss in 53% of breast cancer patients undergoing chemotherapy, with greater hair density and absence of comorbidities enhancing its efficacy, also improving patients' quality of life without increasing scalp metastasis risk.

This article highlights various endocrine disorders and other etiologies linked to alopecia and emphasizes the importance of diagnosing treatable conditions before starting hair loss treatment.

This study found that anti-TNF therapy-induced alopecia exhibits distinct clinical and histopathological features and can mimic psoriatic alopecia and alopecia areata, with some patients improving with topical treatment.